End-of-day quote
Other stock markets
|
||
- USD | - |
May. 15 | Sector Update: Health Care Stocks Advance in Afternoon Trading | MT |
May. 15 | CASI Pharmaceuticals Gets FDA Clearance For Blood Disorder Study | MT |
Financials (USD)
Sales 2024 * | 19.8M | Sales 2025 * | 46.48M | Capitalization | 40.66M |
---|---|---|---|---|---|
Net income 2024 * | -35M | Net income 2025 * | -33M | EV / Sales 2024 * | 2.05 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.87 x |
P/E ratio 2024 * |
-1.22
x | P/E ratio 2025 * |
-1.47
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 50.99% |
Managers | Title | Age | Since |
---|---|---|---|
Wei Wu He
CEO | Chief Executive Officer | 59 | 19-04-01 |
Wei Zhang
DFI | Director of Finance/CFO | 64 | 18-08-31 |
Chun Hua Wang
COO | Chief Operating Officer | 52 | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Wei Wu He
CEO | Chief Executive Officer | 59 | 19-04-01 |
Yue Wu
BRD | Director/Board Member | 62 | 13-03-31 |
Zhen Bo Su
BRD | Director/Board Member | 48 | 23-03-20 |
1st Jan change | Capi. | |
---|---|---|
+37.77% | 705B | |
+32.82% | 583B | |
-3.66% | 364B | |
+20.19% | 332B | |
+4.94% | 291B | |
+16.64% | 238B | |
-4.13% | 210B | |
+10.63% | 209B | |
+8.80% | 169B |